QualityStocks'  Instablog

Send Message
QualityStocks (www.qualitystocks.net) assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with... More
My company:
My blog:
QualityStocks Micro-Cap and Small-Cap Blog
  • Advaxis, Inc. (ADXS) Establishes Blueprint For 2013 Business Achievements 0 comments
    May 30, 2013 12:56 PM | about stocks: ADXS

    Advaxis is a clinical-stage biotech company with a centralized focus on its candidate, ADXS-HPV, which is being evaluated in five clinical trials for HPV-associated diseases: recurrent/refractory cervical cancer, locally advanced cervical cancer, head and neck cancer, and anal cancer.

    In its recent 2013 business outlook, Advaxis said it is pursuing two overarching objectives for 2013 - to advance ADXS-HPV toward registration and development, and to strengthen its financial position - paired with supporting clinical regulatory objectives which are to analyze phase 2 data, proceed with and finalize its clinical plan, and to consult with regulatory authorities to advance ADXS-HPV to registrational trials.

    In 2012 the company began laying serious groundwork to achieve its mission for 2013, securing a $10 million committed equity line, slashing its debt by 80 percent, and achieving proof of concept for ADXS-HPV.

    So far this year, the company has dosed its first patient in a phase 1/2 study of ADXS-HPV in 25 patients with HPV-associated anal cancer .This study expands the clinical investigation of ADXS-HPV to now a third tumor type, following cervical cancer and head and neck cancer.

    The company also recently took a step toward its first licensing deal, announcing that it is working to establish a formal agreement with FusionVax, Inc., a private Taiwan-based biopharmaceutical company developing immunotherapies for the treatment of HPV-associated cancers. Upon final agreement, Advaxis will exclusively license the rights to ADXS-HPV to FusionVax for the Asia territory, exclusive of India, for all indications.

    For the remainder of 2013, Advaxis is on deck to achieve several expectations:

    • Announce CIN 2/3 mid-dose cohort 2 data (Q2)

    • Announce 12-month survival data from India study (Q2)

    • Announce final phase 2 cervical cancer results (H2)

    • Initiate phase 2 high-dose cohort 3 CIN 2/3

    • Complete safety portion of ADXS-cHER2 phase ½ canine study (year-end)

    • Report preliminary data from canine study

    In the first six months of 2014, Advaxis anticipates that it will be prepared to file and IND with the FDA for ADXS-PSA.

    For more information visit advaxis.com

    Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net

    Stocks: ADXS
Back To QualityStocks' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.